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Abstract: Migraine is a common, disabling disorder associated with considerable personal 
and societal burden. Current guidelines recommend triptans for the acute treatment of 
migraine unlikely to respond to less effective therapies. Rizatriptan is a second-generation 
triptan available in tablet or orally disintegrating tablet (wafer) formulations that offers 
several advantages over other members of its class. Rizatriptan is rapidly absorbed from the 
gastrointestinal tract and achieves maximum plasma concentrations more quickly than other 
triptans, providing rapid pain relief. Clinical trials have shown that rizatriptan is at least as 
effective or superior to other oral migraine-speciﬁ  c agents in the acute treatment of migraine, 
and has more consistent long-term efﬁ  cacy across multiple migraine attacks. Rizatriptan has a 
favorable tolerability proﬁ  le, and patients have reported greater satisfaction and a preference 
for rizatriptan over other migraine-speciﬁ  c agents. Improvements in quality of life reported 
with rizatriptan are consistent with its favorable efﬁ  cacy and tolerability proﬁ  les. Notably, 
multi-attribute decision models that combine clinical data with patient- and physician-reported 
treatment preferences have identiﬁ  ed rizatriptan as one of three triptans closest to a hypothetical 
“ideal”. The efﬁ  cacy and tolerability of rizatriptan for the acute treatment of migraine have 
thus been well established.
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Introduction
Background and epidemiology
Migraine is a common, disabling disorder that affects approximately 3%–22% 
of females and 1%–16% of males worldwide (Lipton and Bigal 2005). Results 
of a large population-based study performed in the US suggest that migraine 
affects approximately 18.2% of women and 6.5% of men, of whom most (62%) 
experience at least 1 severe headache per month (Lipton, Stewart, et al 2001). 
Migraine without aura is the commonest clinical subtype of migraine, and has 
a higher attack frequency and is generally more disabling than migraine with 
aura (HCS 2004). Migraine without aura is defined as a recurrent disorder 
that involves headache attacks lasting 4 hours to 3 days, with at least 2 of the 
following characteristics: unilateral pain, pulsating quality, aggravation on 
movement, and pain of moderate or severe intensity (HCS 2004). Patients with 
this migraine subtype also experience nausea and/or vomiting, and/or photophobia 
and phonophobia (HCS 2004).
Migraine places a considerable burden on the sufferer, their friends and family, 
and society, in terms of economic costs and quality of life. Direct costs of migraine 
include visits to physicians, utilization of emergency care facilities, and prescription 
and over-the-counter medications (Lipton and Bigal 2005). The majority of the not 
inconsiderable indirect costs are borne by patients and their employers, predominantly 
as a result of bedridden days and impaired work function (Hu et al 1999). A recent 
analysis, based principally on studies performed prior to 1995, estimated that the 
annual cost of migraine in some Western European countries was approximately Neuropsychiatric Disease and Treatment 2006:2(3) 248
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590 per patient, primarily due to lost productivity (Berg 
and Stovner 2005). Lost productivity due to headache 
(including but not limited to migraine) is estimated to 
cost more than US$19 billion per year in the US, with 
migraine accounting for at least US$13 billion per year 
(Hu et al 1999).
The results of several studies indicate that migraine 
affects quality of life during and immediately after a 
migraine attack, as well as reducing quality of life between 
episodes (Lipton and Bigal 2005). Population-based studies 
in the UK and US demonstrate that migraine attacks also 
have a signiﬁ  cant impact on family members of afﬂ  icted 
individuals (Lipton et al 2003). Moreover, a survey of 
migraine sufferers found that less than one-third of patients 
were “very satisﬁ  ed” with their acute migraine treatment 
(Lipton and Stewart 1999). Thus, migraine remains a 
major healthcare problem, and there is signiﬁ  cant oppor-
tunity to improve the treatment and management of this 
condition.
Current treatments
There are a number of abortive therapy options for acute 
migraine. Nonsteroidal anti-inﬂ  ammatory agents, nonopiate 
analgesics, and combination analgesics may be appropriate 
for some patients with mild-to-moderate migraine. Patients 
with moderate-to-severe symptoms or those who respond 
poorly to adequate doses of analgesics generally require 
migraine-speciﬁ  c agents or more potent nonspeciﬁ  c agents 
such as opiate analgesics, although the latter should be used 
sparingly (Silberstein and for the US Headache Consortium 
2000; Goadsby et al 2002). Anti-emetics may be used to 
treat migraine-associated nausea, and may also facilitate 
absorption of oral migraine treatments by improving gastric 
motility.
The two principal classes of migraine-speciﬁ  c agents 
(ie, those targeting the neurovasculature) are the ergot 
derivatives and the triptans. The ergot derivatives ergota-
mine and dihydroergotamine have been used for the 
acute treatment of migraine for many years. However, 
they have a number of limitations including nonspeciﬁ  c 
vasoconstrictor effects and other side-effects (eg, nausea 
and vomiting) owing to a low degree of receptor selec-
tivity, and there is a lack of consistent efﬁ  cacy data for 
these agents (Tfelt-Hansen, Saxena, et al 2000). Improved 
understanding of the pathology of migraine led to the 
development of selective serotonin (5-hydroxytryptamine 
[5-HT]) receptor agonists (triptans) that activate 5-HT1B 
and 5-HT1D receptors. Triptans are now generally preferred 
over ergot derivatives in treating most patients with 
migraine, because of advantages including selective 
pharmacology and well-established efﬁ  cacy and safety 
(Goadsby et al 2002).
Sumatriptan was the ﬁ  rst triptan to be introduced for 
the treatment of migraine attacks, and is commonly used 
as the reference against which later triptans are compared 
(Ferrari et al 2002). Although clinical trial results show 
only relatively small differences between sumatriptan 
and newer, second-generation triptans for efﬁ  cacy and 
tolerability, these differences are considered clinically 
relevant for individual patients (Ferrari et al 2002). This 
article reviews the evidence relating to rizatriptan, a 
second-generation triptan available in 5- and 10-mg tablets 
and orally disintegrating tablets (wafers) for the acute 
treatment of migraine.
Pharmacology
Animal and preclinical results
Several pharmacologic effects of the 5-HT1B/1D receptor 
agonist rizatriptan are thought to contribute to its antimigraine 
activity, including vasoconstriction of intracranial extrace-
rebral blood vessels (Longmore et al 1998), inhibition of 
nociceptive neurotransmission in trigeminal pain pathways 
(Cumberbatch et al 1997), and inhibition of neurogenic dural 
vasodilation and plasma protein extravasation (Williamson 
et al 1997; Williamson et al 2001).
Preclinical studies showed that rizatriptan caused 
vasoconstriction in isolated human cranial (middle 
meningeal) arteries (Longmore et al 1998) with an EC50 
(concentration required to produce 50% of maximum 
vasoconstriction) of 90 nM, which is similar to the 
maximum plasma concentrations achieved following oral 
administration of a single 5- or 10-mg rizatriptan dose in 
healthy individuals (30–70 nM) (Sciberras et al 1997). 
The vasoconstrictor action of rizatriptan is thought to 
occur primarily via 5-HT1B receptors (Longmore et al 
1998; Goadsby and Hargreaves 2000). A study in healthy 
volunteers showed that rizatriptan signiﬁ  cantly reduced 
cerebral blood ﬂ  ow and arterial-to-capillary blood volume 
consistent with its vasoconstrictor activity in large cerebral 
arteries, with a recovery pattern indicating no alteration 
of the autoregulatory response of small arteries (Okazawa 
et al 2005). Another study in healthy volunteers found no 
effect of rizatriptan 40 mg on regional cerebral blood ﬂ  ow 
(Sperling and Tfelt-Hansen 1995). Furthermore, rizatriptan 
did not signiﬁ  cantly alter cerebral blood ﬂ  ow velocity during 
attacks in patients with migraine without aura as compared Neuropsychiatric Disease and Treatment 2006:2(3) 249
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with pretreatment or pain-free values, a ﬁ  nding that may 
support the cerebrovascular safety of the drug (Gori et al 
2005). Although, like other triptans, rizatriptan has also 
been shown to contract isolated human coronary arteries 
in vitro (Longmore et al 1997; MaassenVanDenBrink et al 
1998), the EC50 for this effect (700–1000 nM) (Longmore 
et al 1997) is so high that rizatriptan is considered unlikely 
to cause myocardial ischemia at therapeutic plasma con-
centrations in patients with normal coronary circulation 
(MaassenVanDenBrink et al 1998). Rizatriptan 10 mg 
demonstrated only minimal and transient vasoconstrictor 
effects on peripheral arteries in normal human subjects 
(Tfelt-Hansen et al 2002).
Pharmacokinetics
Rizatriptan is rapidly and completely (∼90%) absorbed 
from the gastrointestinal tract following administra-
tion of the oral tablet, with an absolute bioavailabil-
ity of 47% owing to moderate first-pass metabolism 
(Vyas et al 2000). The mean time to maximum plasma 
concentration (tmax) following a single rizatriptan 10-mg 
tablet in healthy volunteers is approximately 1–1.5 hours 
(Sciberras et al 1997; Goldberg et al 2000; Vyas et al 
2000), which is shorter than that of other available 
triptans (Ferrari et al 2002). Rizatriptan has a relatively 
short plasma half-life (t1/2) of approximately 2–2.5 hours 
(Sciberras et al 1997; Lee et al 1999; Goldberg et al 
2000; Vyas et al 2000). A pharmacokinetic study in 
healthy males showed no unexpected accumulation of 
rizatriptan 10 mg following administration of multiple 
doses (every 2 hours for 3 doses on 4 consecutive days) 
(Goldberg et al 2000). Rizatriptan wafers have a similar 
pharmacokinetic proﬁ  le to tablets, although they have a 
slower rate of absorption (mean tmax 1.6–2.5 hours) (Merck & 
Co Inc. 2003).
Metabolism is the primary route of elimination of 
rizatriptan, with renal elimination accounting for only 25% 
of total plasma clearance (Vyas et al 2000). Rizatriptan 
is metabolized predominantly by monoamine oxidase A, 
accounting for 51% of urinary rizatriptan metabolites (Vyas 
et al 2000). The clearance of rizatriptan is approximately 25% 
higher in males than in females (plasma clearance 1042 vs 
821 mL/min, respectively); however, this is not thought to 
be clinically relevant (Lee et al 1999).
Importantly, rizatriptan mean plasma concentrations 
and tmax are not affected by the occurrence of a migraine 
attack (and associated gastric stasis) (Cutler et al 1999). 
Administration of food prior to rizatriptan dosing in healthy 
volunteers was found to increase the area under the curve 
(AUC) by approximately 20% and delay absorption, but there 
were no signiﬁ  cant effects on maximum concentration (Cmax) 
or tmax values (Cheng et al 1996). The pharmacokinetics of 
rizatriptan in elderly patients (aged   65 years) are similar 
to those in younger patients (Musson et al 2001). Since 
the major route of elimination of rizatriptan, oxidative 
deamination, is catalyzed by monoamine oxidase A, inhibitors 
of cytochrome P-450 are expected to have minimal effects 
on the pharmacokinetics of rizatriptan (Vyas et al 2000). 
Patients receiving propranolol exhibit an increase in 
plasma rizatriptan concentration (Goldberg et al 2001), 
possibly reﬂ  ecting competitive inhibition of monoamine 
oxidase A rizatriptan metabolism. Rizatriptan dose-
reduction is therefore recommended in patients receiving 
propranolol (see patient support–disease management 
programs section).
Clinical studies
Efﬁ  cacy
Recommended efﬁ  cacy measures in clinical trials of migraine 
treatments include the percentage of patients who are pain-
free at 2 hours following treatment, headache response–pain 
relief at 2 hours (reduction in intensity of the headache from 
severe or moderate at baseline to mild or none), sustained 
pain-free response rate (pain-free status within 2 hours 
with no rescue medication use or migraine recurrence 
within 48 hours), time to headache response or pain-free 
status (ie, speed of onset of action), and the need for rescue 
medications within 2 hours of treatment (Tfelt-Hansen, 
Block, et al 2000).
The efﬁ  cacy of rizatriptan 5 and 10 mg in acute migraine 
has been clearly established in randomized, double-blind, 
placebo-controlled trials (Visser et al 1996; Gijsman et al 
1997; Goldstein et al 1998; Teall et al 1998; Tfelt-Hansen 
et al 1998; Ahrens et al 1999; Bomhof et al 1999; Pascual 
et al 2000; Kolodny et al 2004). A meta-analysis of 
7 phase III, randomized, double-blind, placebo-controlled 
trials in which a total of 4814 patients received treatment for 
at least 1 migraine attack demonstrated that rizatriptan 10 mg 
was signiﬁ  cantly more effective than placebo at 2 hours on 
measures of pain relief, pain-free status, nausea, photophobia, 
phonophobia, and functional disability (p   0.001 for all 
comparisons) (Ferrari et al 2001). Furthermore, compared 
with placebo recipients, signiﬁ  cantly more patients taking 
rizatriptan 10 mg had sustained pain relief (18% vs 37%, 
respectively, p   0.001) and pain-free status (7% vs 25%, 
p   0.001) over 24 hours. The results of these trials have Neuropsychiatric Disease and Treatment 2006:2(3) 250
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been further conﬁ  rmed in a large open-label, uncontrolled 
study (Göbel et al 2001).
In randomized comparative studies, rizatriptan 10 mg 
was at least as effective as, or superior to, oral sumatriptan 
50 or 100 mg (Visser et al 1996; Goldstein et al 1998; Tfelt-
Hansen et al 1998; Kolodny et al 2004), zolmitriptan 2.5 mg 
(Pascual et al 2000), naratriptan 2.5 mg (Bomhof et al 1999), 
and ergotamine–caffeine 2 mg/200 mg (Christie et al 2003) 
for a number of efﬁ  cacy parameters, including headache 
relief and pain-free status at 2 hours, functional improve-
ment at 2 hours, and time to headache–pain relief (Table 1, 
Figure 1). The proportion of patients experiencing head-
ache recurrence was generally similar between patients 
taking rizatriptan and those taking comparator treatments. 
However, statistical analyses of this endpoint are usually 
not performed because recurrence is conditional on initial 
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Figure 1 Patients reporting pain relief at time points up to 2 hours following dosing with rizatriptan or sumatriptan in a randomized, double-blind, placebo-controlled, 
cross-over study (Goldstein et al 1998). Adults with at least a 6-month history of migraine with or without aura were randomized to treat 2 sequential migraine attacks of 
moderate to severe intensity separated by at least 5 days. Treatment sequences included (a) rizatriptan 5 mg followed by sumatriptan 25 mg or vice versa, (b) rizatriptan 
10 mg followed by sumatriptan 50 mg or vice versa, or placebo followed by placebo (data not shown). Hazard ratios for time to pain relief indicate that patients receiving 
rizatriptan were signiﬁ  cantly more likely to achieve pain relief during the 2-hour period than patients receiving sumatriptan. *p   0.05. Reproduced from Goldstein J, Ryan R, 
Jiang K, et al. 1998. Crossover comparison of rizatriptan 5 mg and 10 mg vs sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache, 
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headache relief and confounded by the use of additional 
headache–pain medication, thus making interpretation of 
recurrence rates difﬁ  cult.
Analyses of data from several of the above-mentioned 
comparator studies (Tfelt-Hansen et al 1998; Goldstein et al 
1998; Bomhof et al 1999; Pascual et al 2000; Kolodny et al 
2004) have conﬁ  rmed the signiﬁ  cantly greater efﬁ  cacy of 
rizatriptan 10 mg compared with oral sumatriptan 25, 50, 
or 100 mg, naratriptan 2.5 mg, and zolmitriptan 2.5 mg 
for stringent efficacy measures (pain-free response at 
2 hours, symptom-free response at 2 hours, and 24-hour 
sustained pain-free response) (Adelman et al 2001), ability 
to functional normally at 2 hours (Bussone et al 2002), and 
freedom from nausea at 2 hours (sumatriptan and naratriptan) 
(Lipton, Pascual, et al 2001) (Table 2).
Open-label trials have also shown beneﬁ  ts with rizatriptan 
10 mg wafer vs oral sumatriptan 50 mg (Pascual et al 2001; 
Loder et al 2001), almotriptan 12.5 mg (Leira et al 2003), 
and zolmitriptan 5 mg (Mathew et al 2000), on efﬁ  cacy mea-
sures such as greater headache relief and/or freedom from 
pain at 2 hours (vs sumatriptan and zolmitriptan), faster time 
to headache relief and pain-free status (vs sumatriptan) and 
reductions in number of triptan doses needed for migraine 
(vs almotriptan). A small single-blind, single-center, 
multiple-attack study comparing rizatriptan 10 mg, sumat-
riptan 100 mg, almotriptan 12.5 mg, zolmitriptan 2.5 mg, 
and eletriptan 40 mg, reported relatively homogeneous 
results overall, but superior efﬁ  cacy with rizatriptan with 
respect to pain-free response at 2 hours (vs sumatriptan and 
almotriptan) and sustained pain-free response (vs sumatrip-
tan) (Vollono et al 2005). The authors considered rizatriptan 
to have the best performance of the triptans evaluated but 
concluded that, owing to the unpredictability of responsive-
ness to individual triptans, selection of an “ideal triptan” may 
require a process of trial and error in each patient (Vollono 
et al 2005).
Patients treated with rizatriptan 10-mg tablet or wafer 
in a typical patient care setting reported better treatment 
outcomes compared with their prior migraine treatment 
experiences (primarily triptans, opiates and barbiturates, or 
nonsteroidal anti-inﬂ  ammatory drugs), in terms of speed of 
pain relief (18% and 23% of patients taking rizatriptan tablet 
or wafer, respectively, reported onset of pain relief within 
30 minutes vs 16% for comparator), and 2-hour efﬁ  cacy 
endpoints including headache response (66% and 67% vs 
37%), pain-free status (31% for both rizatriptan formula-
tions vs 12%), freedom from migraine-associated symptoms 
(52% and 54% vs 35% largely symptom-free), and ability to 
resume normal activities (50% and 51% vs 31%) (Jamieson 
et al 2003). Similarly, an open-label, 2-attack study showed 
that among patients with functional disability at the start of 
a migraine attack, more patients reported a return to normal 
function 2 hours after treatment with rizatriptan 10-mg 
wafer than after treatment of the preceding attack with their 
usual nontriptan therapy (nonsteroidal anti-inﬂ  ammatory 
drugs, analgesics, or ergot derivatives, used alone or in 
combination) (48% vs 19%, respectively; p   0.001) 
(Pascual et al 2005). After adjusting for confounding factors, 
rizatriptan was twice as likely to return patients to normal 
function compared with their usual nontriptan therapy 
(hazard ratio 2.08; 95% conﬁ  dence interval, 1.92–2.25; 
p   0.001), and the speed of return to normal function was 
signiﬁ  cantly greater with rizatriptan therapy (p   0.001) 
(Pascual et al 2005).
Long-term studies (up to 6 months or 1 year) of acute 
treatment with rizatriptan tablets (Block et al 1998) or wafers 
(Cady et al 2001) for multiple attacks showed that rizatriptan 
10 mg was superior to rizatriptan 5 mg or “standard care” 
in terms of pain relief and pain-free status at 2 hours after 
dosing (Figure 2). Headache relief rates were consistently 
maintained over the duration of the studies, with no appar-
ent change in response over time. Importantly, there was 
no evidence of tolerance to the therapeutic effects of riza-
triptan after up to 1 year of treatment (Block et al 1998). 
Rizatriptan also demonstrated consistent within-patient 
efﬁ  cacy over multiple migraine attacks (Kramer et al 1998; 
Dahlof et al 2000).
Quality of life beneﬁ  ts, as measured by the 24-hour 
Migraine Quality of Life Questionnaire (Santanello et al 
1995), have also been reported with rizatriptan treat-
ment. In randomized controlled trials, rizatriptan 10 mg 
was associated with signiﬁ  cantly better migraine-speciﬁ  c 
quality of life than placebo (p = 0.005) (Santanello et al 
1997), and provided improvements in 24-hour quality of 
life relative to baseline similar to those achieved with oral 
sumatriptan 25, 50, or 100 mg (Goldstein et al 1998), zolmi-
triptan 2.5 mg (Pascual et al 2000), and naratriptan 2.5 mg 
(Bomhof et al 1999). One study found that rizatriptan 10 mg 
was superior to rizatriptan 5 mg in this regard (p   0.001) 
(Santanello et al 1997).
Rizatriptan has demonstrated efﬁ  cacy in special patient 
groups. In a retrospective analyses of data from a sub-
group of women with menstrual migraine from 2 randomized 
placebo-controlled trials, rizatriptan (5 or 10 mg) was 
signiﬁ  cantly more effective than placebo in achieving pain 
relief and pain-free status at 2 hours (p   0.05 for both Neuropsychiatric Disease and Treatment 2006:2(3) 253
Rizatriptan in migraine
endpoints) (Silberstein et al 2000). Results from this and 
another retrospective analysis of data from a long-term (up to 
6 months) extension study suggest that rizatriptan has similar 
efﬁ  cacy in patients with menstrual migraine to that observed 
in patients with nonmenstrual migraine (Silberstein et al 
2002). Rizatriptan 5 mg tablets or wafers were more effec-
tive in achieving 2-hour pain relief and pain-free status than 
standard care (primarily ibuprofen, sumatriptan, zolmitriptan, 
and aspirin–acetaminophen–caffeine) in adolescents aged 
12–17 years, based on pooled data from 2 long-term, open-
label studies (Visser et al 2004). In 2 randomized, double-
blind, single-attack studies in adolescent patients, rizatriptan 
5 mg tablets were not signiﬁ  cantly different from placebo 
for pain relief or freedom from pain at 2 hours (Winner et al 
2002; Visser et al 2004); however, there were high placebo 
response rates in both trials (eg, 2-hour pain relief rates with 
rizatriptan vs placebo were 66% vs 56% (Winner et al 2002) 
and 68% vs 69% (Visser et al 2004), respectively).
In most clinical trials rizatriptan was generally admin-
istered to patients with moderate-to-severe headaches; 
however, rizatriptan has also shown efﬁ  cacy when given for 
mild pain in the early stages of a migraine attack (Mathew 
et al 2004).
A meta-analysis of results from 53 studies of oral triptans 
in the treatment of migraine showed that rizatriptan 10 mg 
appeared to have greater intra-patient consistency for 2-hour 
headache response and pain-free status over 3 migraine 
attacks than other triptan dosages evaluated (sumatriptan 
25–100 mg, naratriptan 2.5 mg, eletriptan 20–80 mg, and 
almotriptan 12.5 mg) (Ferrari et al 2002). The analysis 
indicated that rizatriptan 10 mg (along with eletriptan 80 mg 
and almotriptan 12.5 mg) was one of three triptans most 
likely to be associated with consistent treatment success, 
particularly when rapid and consistent relief of pain was 
required (Ferrari et al 2002).
Tolerability and patient 
acceptability
Rizatriptan was generally well tolerated in the aforementioned 
randomized, placebo-controlled studies. The frequency of 
adverse events with rizatriptan appears to be dose-related 
(Visser et al 1996; Ferrari et al 2001). In a summary of 
adverse event data from 7 randomized, placebo-controlled 
studies of rizatriptan for the acute treatment of migraine 
attack, speciﬁ  c adverse events with an incidence of 5% or 
more in patients receiving placebo (n = 1260), rizatriptan 
5 mg (n = 1486), or rizatriptan 10 mg (n = 2068) were dizzi-
ness (4%, 6%, and 9%, respectively), somnolence (4%, 5%, 
and 8%), nausea (4%, 5%, and 6%), and asthenia–fatigue (2%, 
3%, and 5%) (Ferrari et al 2001). Similarly, the most common 
adverse events in patients taking rizatriptan 5- or 10-mg 
tablet or wafer in comparative clinical trials included dizzi-
ness (5%–11% of patients across clinical trials), somnolence 
(4%–10%), asthenia–fatigue (2%–8%), dry mouth (2%–7%), 
nausea (2%–6%), and chest pain (1%–4%); these events 
were predominantly transient and mild or moderate in inten-
sity (Visser et al 1996; Goldstein et al 1998; Tfelt-Hansen 
et al 1998; Bomhof et al 1999; Pascual et al 2000; Christie 
et al 2003; Kolodny et al 2004). In comparator studies, the 
overall incidence of drug-related adverse events in patients 
receiving rizatriptan 5- or 10-mg tablet or wafer ranged 
from 23% to 37%, compared with sumatriptan 25, 50, or 
100 mg (28%  –41%), zolmitriptan 2.5 mg (28%), naratrip-
tan 2.5 mg (19%), and ergotamine 2 mg–caffeine 200 mg 
(23%) (Bianchi et al 1989; Goldstein et al 1998; Tfelt-
Hansen et al 1998; Bomhof et al 1999; Christie et al 2003; 
Table 2 Efﬁ  cacy of rizatriptan in the acute treatment of migraine in retrospective analyses of comparative studies
Proportion of patients achieving efﬁ  cacy measures, % (odds ratio)
Agents by dose
(mg) and
compator
Pain-free at 2 hours
(Adelman
et al 2001)
Symptom-free at
2 hours (Adelman
et al 2001)
24-hour sustained
pain-free response
(Adelman
et al 2001)
Normal function
at 2 hours
(Bussone
et al 2002)
Nausea-free at
2 hours
(Lipton
et al 2001)
R 10 S 25 38% (1.7)a27% 33% (1.6)a24% 27% (1.5)a20% 48% (1.7)a36% 68% (1.4)b59%
R 10 S 50 40% (1.2)b35% 33% (1.2)a28% 30% (1.2)b26% 47% (1.2)b42% 68% (1.5)b57%
R 10 S 100 40% (1.4)b33% 31% (1.7)a22% 27% (1.3)c23% 39% (1.4)b32% 66% (1.4)b58%
R 10 N 2.5 45% (3.3)a21% 30% (3.6)a11% 29% (2.0)a17% 39% (2.5)a22% 59% (1.8)b45%
R 10 Z 2.5 43% (1.4)b36% 31% (1.4)b24% 32% (1.6)b24% 45% (1.6)b36% 65% (1.3)c61%
ap   0.005 vs comparator.
bp   0.05 vs comparator.
cNonsigniﬁ  cant difference vs comparator (p   0.05).
Abbreviations: N, naratriptan; R, rizatriptan; S, sumatriptan; Z, zolmitriptan.Neuropsychiatric Disease and Treatment 2006:2(3) 254
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Kolodny et al 2004). One study reported a signiﬁ  cantly lower 
adverse event rate in patients receiving rizatriptan 5 and 
10 mg vs sumatriptan 100 mg (27% and 33%, respectively, vs 
41%; p   0.05) (Tfelt-Hansen et al 1998). Rizatriptan 5-mg 
tablets and wafers were also well tolerated in adolescents 
(Winner et al 2002; Visser et al 2004). Most studies reported 
no serious drug-related adverse events, and very few patients 
discontinued due to adverse events.
In a large, open, noncomparative study involving 33147 
patients receiving treatment with rizatriptan 10 mg in a clinical 
setting for up to 3 migraine attacks, repeated administration 
of rizatriptan was well tolerated, with very few adverse events 
reported (Göbel et al 2001). In this study, 0.9% of patients 
experienced 1 or more adverse events, the most frequent 
of which were dizziness (0.2%) and weakness–fatigue 
(0.2%). A total of 157 patients discontinued rizatriptan 
owing to an unwanted drug effect, representing 6.3% of 
all patients who discontinued rizatriptan for any reason 
and 0.5% of patients enrolled on the study. Fewer than 
4.5% of patients taking rizatriptan 5 or 10 mg withdrew 
because of adverse events in long-term studies of rizat-
riptan treatment for multiple migraine attacks (Block et al 
1998; Cady et al 2001).
In the randomized, double-blind, comparative trials, 
rizatriptan 10 mg was associated with a higher degree 
of patient satisfaction with medication compared with 
sumatriptan 50 mg (mean satisfaction on a scale from 1 
“completely satisﬁ  ed; couldn’t be better” to 7 “completely 
dissatisﬁ  ed; couldn’t be worse”: 3.28 vs 3.56 at 2 hours 
and 3.06 vs 3.39 at 4 hours; p   0.05 both comparisons) 
(Goldstein et al 1998), zolmitriptan 2.5 mg (mean 3.38 vs 
3.67 at 2 hours; p = 0.038) (Pascual et al 2000), naratriptan 
2.5 mg (mean 3.55 vs 4.21 at 2 hours; p   0.001) (Bomhof 
et al 1999), and ergotamine 2 mg–caffeine 200 mg (43.8% 
vs 21.6% of patients completely satisﬁ  ed or very satisﬁ  ed at 
2 hours; p   0.001) (Christie et al 2003).
In a randomized, open-label, crossover trial designed 
to compare preference for rizatriptan 10-mg wafers vs 
sumatriptan 50-mg tablets, significantly more patients 
preferred rizatriptan than preferred sumatriptan (64.3% vs 
35.7%; p   0.001) (Pascual et al 2001). The most com-
mon reasons for rizatriptan treatment preference were 
faster relief of headache pain (46.9% of patients), ease of 
use (8.2%), and fewer side-effects (6.1%). Similar results 
were seen in a second trial of similar design, with 57% of 
patients expressing a preference for rizatriptan 10-mg wafers 
compared with 43% of patients who preferred sumatriptan 
50-mg tablets (p = 0.009) (Loder et al 2001). Among those 
patients with a stated preference, the most important reasons 
were faster pain relief (51% of patients), the ability to take 
the medication regardless of patient location (8%; only 
reported for rizatriptan wafer), and the ability to return to 
normal activities quicker (7%). It is possible that treatment 
choice could have been inﬂ  uenced by the ease of use of the 
ab
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Figure 2 Median percent of migraine attacks in which patients achieved pain relief or pain-free status 2 hours after dosing. (a) Results in patients enrolled in an open-label, 
randomized, 6-month extension study who treated at least 1 moderate or severe migraine attack with rizatriptan 5-mg wafers (median of 16 attacks treated), rizatriptan 
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rizatriptan wafer formulation in these 2 studies. However, 
a relatively small percentage of patients reported this as the 
reason for treatment preference, and results of a separate 
retrospective nonblinded study in 367 patients showed that 
a similar number of patients preferred the 10-mg wafer 
(n = 188) and 10-mg tablet (n = 179) rizatriptan formula-
tions (Adelman et al 2000), suggesting that formulation was 
probably not the key factor.
A greater proportion of patients preferred rizatriptan 
10-mg tablets than preferred ergotamine 1-mg–caffeine 
100-mg tablets in a randomized, double-blind, crossover 
trial (69.9% vs 30.1% of 319 patients expressing a prefer-
ence, respectively; p   0.001), with faster relief of headache 
cited by the majority of these patients (67.3% vs 54.2%, 
respectively) as the most important reason for preference 
(Christie et al 2003).
Similarly, among patients who reported a treatment 
preference in a prospective, open-label, 2-attack study, 
more patients preferred rizatriptan 10-mg wafers than 
preferred their usual nontriptan therapy (nonsteroidal anti-
inﬂ  ammatory drugs, analgesics, or ergot derivatives, used 
alone or in combination) (78.8% vs 21.2%, respectively; 
p   0.001). Overall, the most common reasons cited for pref-
erence of either treatment were faster relief of headache pain 
and faster return to normal function (Pascual et al 2005).
The quality of life beneﬁ  ts afforded by rizatriptan, as 
mentioned above (Santanello et al 1997; Goldstein et al 
1998; Bomhof et al 1999; Pascual et al 2000), are consis-
tent with the favorable efﬁ  cacy and tolerability proﬁ  le of 
the agent.
Patient support and disease 
management programs
The goals of migraine management are to treat attacks rapidly 
and consistently without recurrence, restore the patient’s 
ability to function, minimize the use of rescue medications, 
optimize self-care and subsequent resource use, be cost effec-
tive, and have minimal or no adverse events (Silberstein and 
for the US Headache Consortium 2000).
British Association for the Study of Headache 2004 
guidelines recommend a stepwise treatment approach 
as a means of achieving individualized therapy, starting 
patients on the safest and cheapest agents with known 
efﬁ  cacy (BASH 2004). Treatment steps in ascending order 
are (i) a simple oral analgesic (eg, aspirin) with or without 
an antiemetic, (ii) a parenteral analgesic (eg, diclofenac) 
with or without an antiemetic, and (iii) a migraine-speciﬁ  c 
agent (eg, triptan). Patients should start on the ﬁ  rst step, 
with treatment failure on 3 occasions being the suggested 
criterion for progression from one step to the next. The 
guidelines note that different treatment steps may be used in 
individual patients who experience attacks of different types 
or severities. The American Academy of Family Physicians 
and American College of Physicians–American Society of 
Internal Medicine (AAFP/ACP–ASIM) also recommend a 
stepwise treatment approach (Snow et al 2002).
In contrast, United States Headache Consortium 2000 
guidelines advocate stratiﬁ  ed treatment according to the 
severity of an individual migraine attack (Silberstein and 
for the US Headache Consortium 2000). Migraine-speciﬁ  c 
agents (eg, triptans) are recommended for the initial acute 
treatment of moderate-to-severe migraine where there are no 
contraindications for their use. Triptans are also considered 
appropriate for patients with mild-to-moderate headaches 
that respond poorly to nonsteroidal anti-inﬂ  ammatory drugs 
or combinations such as aspirin plus caffeine (Silberstein 
and for the US Headache Consortium 2000). The relative 
beneﬁ  ts of stepwise and stratiﬁ  ed treatment, and the place 
of triptans in initial migraine therapy, remain a matter for 
debate. However, there is evidence that stratiﬁ  ed treatment 
provides more effective headache relief for patients with 
moderate-to-severe migraine-related disability than stepwise 
strategies used within or between migraine attacks (Lipton 
et al 2000).
While triptans are unlikely to cause substantial coronary 
vasoconstriction in patients with relatively healthy coronary 
arteries, their effects may be less predictable in patients with 
coronary artery disease; therefore, triptans are contraindi-
cated in patients with ischemic heart disease, uncontrolled 
hypertension, a history of coronary vasospasm, and patients 
at high risk of asymptomatic coronary artery disease (Martin 
and Goldstein 2005). Concerns about the cardiovascular 
safety of the triptans led to an evaluation of triptan-
associated cardiovascular risk by the Triptan Cardiovascular 
Safety Expert Panel of the American Headache Society, 
and a consensus statement arising from this evaluation 
concluded that triptans can be prescribed with conﬁ  dence 
in patients with low risk of coronary artery disease (Dodick 
et al 2004).
Patients report greater satisfaction with migraine-
speciﬁ  c triptan therapy than with analgesics, nonsteroidal 
anti-inﬂ  ammatory drugs, or ergot derivatives (Ceballos 
Hernansanz et al 2003). British Association for the Study 
of Headache guidelines state that among the triptans, rizat-
riptan 10-mg tablet or wafer formulations are an appropriate Neuropsychiatric Disease and Treatment 2006:2(3) 256
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choice for patients who require stronger oral treatment 
than sumatriptan (although, due to the pharmacological 
interaction described above [see pharmacokinetics section], 
patients receiving prophylactic propranolol should take 
rizatriptan 5 mg) (BASH 2004). United States Headache 
Consortium guidelines (Silberstein and for the US Headache 
Consortium 2000) make no recommendations as to which 
triptan should be selected. However, consideration should 
be given to those features considered by patients and physi-
cians as being important in a migraine treatment. Research 
has shown that although a variety of attributes are desirable, 
rapid onset of complete pain relief is considered particularly 
important both by clinicians and patients (Lipton et al 2002). 
In a survey of US primary care physicians, rapid achievement 
of pain-free and sustained pain-free status were considered 
the most important efﬁ  cacy attributes of triptan treatment 
(Cutrer et al 2004).
The TRIPSTAR project was developed to help physi-
cians select oral triptans to best match patient needs by 
combining data on patient- and physician-reported treatment 
preferences with results from the aforementioned meta-
analysis of triptan clinical trial data (see efﬁ  cacy section) 
(Lipton et al 2005). When the data from the meta-analysis 
were evaluated using a Technique for Order Preference by 
Similarity to the Ideal Solution (TOPSIS) multi-attribute 
decision model, which considers attributes of the triptans 
weighted according to patient- and physician-reported 
treatment preferences, rizatriptan, along with almotriptan 
and eletriptan, was one of the closest available treatments 
to the hypothetical “ideal” triptan (deﬁ  ned as the best 
achievable with current technology) (Lipton et al 2005). 
It is interesting to note that the superiority of rizatriptan, 
almotriptan, and eletriptan relative to sumatriptan, nara-
triptan, and zolmitriptan in the above analysis was sup-
ported by a separate analysis using a TOPSIS model that 
considered all possible treatment attribute weightings, rather 
than importance weights determined in a particular study 
(Ferrari et al 2005).
The potential economic beneﬁ  ts of rizatriptan therapy 
may also be taken into account when selecting from 
among the oral triptans. An open-label workplace study 
in 259 Spanish migraineurs showed that treatment with 
rizatriptan for 3 months led to signiﬁ  cant reductions in 
the use of medical services, absenteeism, and loss of 
productivity, as well as improved quality of life compared 
with the 3 months before starting rizatriptan (Láinez et al 
2005). Similarly, a recent analysis determined that sub-
stantial productivity costs of migraine to the US employer 
could be signiﬁ  cantly reduced if rizatriptan were used 
instead of patients’ existing therapies (Gerth et al 2004). 
Moreover, a US cost-effectiveness analysis performed 
from a societal perspective showed that rizatriptan was 
more cost-effective in the treatment of acute migraine 
than sumatriptan or ergotamine–caffeine, reﬂ  ecting both 
reduced costs and greater effectiveness (as measured by 
quality-adjusted life-years gained) (Zhang and Hay 2005). 
In a meta-analysis of randomized, placebo-controlled 
trials of single-dose oral triptans, rizatriptan 10 mg had 
the most advantageous cost-effectiveness ratio vs other 
triptans (almotriptan, eletriptan, frovatriptan, naratriptan, 
zolmitriptan, and sumatriptan) when results were com-
pared using drug cost data from the US, the UK, Canada, 
Germany, Italy, and The Netherlands, although the levels 
of statistical signiﬁ  cance vs comparators varied between 
countries (Belsey 2004).
Conclusion
According to current guidelines advocating stepwise or 
stratiﬁ  ed treatment approaches, triptans are recommended 
for the acute treatment of migraine unlikely to respond 
to less effective therapy. A number of triptans are avail-
able; however, rizatriptan has several advantages over 
other members of its class (Table 3). Rizatriptan reaches 
maximum plasma concentrations quickly, with a shorter 
tmax than other available triptans, and produces rapid onset 
of pain relief. This may prove advantageous in the early 
treatment of migraine, allowing rapid relief of mild pain 
before an attack becomes moderate to severe. Comparative 
clinical trials have shown that for the acute treatment of 
migraine rizatriptan is at least as effective as, or superior 
to, other oral migraine-speciﬁ  c agents. Rizatriptan has 
demonstrated efﬁ  cacy over the long term (up to 12 months) 
in the treatment of multiple migraine attacks, and appears 
to have more consistent efﬁ  cacy across multiple attacks 
than other triptans. Rizatriptan is generally well tolerated, 
with an overall incidence of adverse events and quality 
of life beneﬁ  ts similar to other triptans. It is associated 
with a higher degree of patient satisfaction than other 
migraine-speciﬁ  c agents, with rapid pain relief, ease of 
use (wafer formulation), and tolerability being important 
reasons for patient preference. Multi-attribute decision 
models incorporating efﬁ  cacy data and weighted clinical 
attributes identify rizatriptan as one of three triptans closest 
to a hypothetical ideal. In conclusion, rizatriptan is a well-
established, effective, and well-tolerated agent for the acute 
treatment of migraine.Neuropsychiatric Disease and Treatment 2006:2(3) 257
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